Home › Mutual Funds › Nippon Mutual Fund › Nippon India Pharma Fund - Growth
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Growth

Add To Compare

previously known as Reliance Pharma Gr until

510.122 (0.787%)
NAV on December 19, 2025
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 8,459 cr
Turnover Ratio 14.27%
Expense Ratio 1.81%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: -1.62%
  • 1Y: -1.45%
  • 3M: -2.61%
  • 3Y: 21.62%
  • 6M: 1.58%
  • 5Y: 15.37%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 20 years) Kinjal Desai (Since over 7 years) Lokesh Maru (Since 4 months) Divya Sharma (Since 4 months)
ISIN INF204K01968
Fund Family Nippon
P/E Ratio 35.82
P/B Ratio 5.53
Launch Date June 05, 2004
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -1.11
Beta 0.91
R-Squared 94.80
Info Ratio -0.77
Tracking Err 3.74
Sortino 1.621
Sharpe 0.918
Std Dev 15.229
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet
-
Best Sector Healthcare Funds
NAME LATEST
NAV		 RETURNS
1y     		FUND
ASSETS		 Expense
RATIO		 RISK
Icici
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
43.150 3.08% 6,460 cr 1.03% -
Uti
UTI Healthcare Fund-Growth Option- Direct
322.851 -0.47% 1,126 cr 1.3% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon Fund